James O. Armitage Clinical Investigator Award: Matthew S. Davids, MD, MMSc, received the James O. Armitage Clinical Investigator Award at the Pan Pacific Lymphoma Conference in Maui. Here, Matthew Lunning, DO, (at podium) introduces the award and Julie Vose, MD, presents the award to Dr. Davids (center).
Matthew S. Davids, MD, MMSc, is the recipient of the first James O. Armitage Clinical Investigator Award, presented at the 2018 Pan Pacific Lymphoma Conference in July in Maui. Dr. Davids is Director of the Lymphoma BioBank and Assistant Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, Boston. James O. Armitage, MD, FASCO, is the Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center, Omaha, and is also the Editor-in-Chief of The ASCO Post.
Introducing Dr. Davids was Matthew A. Lunning, DO, Assistant Professor at the University of Nebraska Medical Center. Dr. Lunning noted that his first interaction with Dr. Armitage while a medical student “changed his career trajectory forever.” The award presented at the conference recognized Dr. Armitage’s “decades of willingness to pick up the phone, his guidance of young and mature souls toward a path of success, and his steadfast advocacy of professional integrity.”
Accepting the award, Dr. Davids commented that his own professional story “is one of being in the right place at the right time and, importantly, working with the right people…in developing new drugs for lymphoma patients.” He remarked upon Dr. Armitage’s “remarkable career—4 decades plus—in clinical care, investigation, and mentorship. It’s truly an honor to receive this first James O. Armitage Clinical Investigator Award.” ■
Although many agents have been able to successfully inhibit the proliferative capacity of cancer cells or disable mutations that spur cancer growth, one area that has proven elusive is the apoptotic pathway—the cell’s means of resisting death. That is until recently.
It may seem...!-->!-->